![]() | |
![]() | |
Clinical data | |
---|---|
Pronunciation | /ɒksiˈkoʊdoʊn/ |
Trade names | Roxicodone, OxyContin, others |
Other names | Eukodal, eucodal; dihydrohydroxycodeinone, 7,8-dihydro-14-hydroxycodeinone, 6-deoxy-7,8-dihydro-14-hydroxy-3-O-methyl-6-oxomorphine |
AHFS/Drugs.com | Monograph |
MedlinePlus | a682132 |
License data | |
Pregnancy category |
|
Dependence liability | High |
Addiction liability | High |
Routes of administration | By mouth, sublingual, intramuscular, intravenous, intranasal, subcutaneous, transdermal, rectal, epidural |
Drug class | Opioid |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | By mouth: 60–87% |
Protein binding | 45% |
Metabolism | Liver: mainly CYP3A, and, to a much lesser extent, CYP2D6 (~5%); 95% metabolized (i.e., 5% excreted unchanged) |
Metabolites | • Noroxycodone (25%) • Noroxymorphone (15%, free and conjugated) • Oxymorphone (11%, conjugated) • Others (e.g., minor metabolites) |
Onset of action | IR : 10–30 minutes CR : 1 hour |
Elimination half-life | IR: 2–3 hours CR: 4.5 hours |
Duration of action | IR: 3–6 hours CR: 10–12 hours |
Excretion | Urine (83%) |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
Chemical and physical data | |
Formula | C18H21NO4 |
Molar mass | g·mol−1 |
3D model (JSmol) | |
Melting point | 219 °C (426 °F) |
Solubility in water | 166 (HCl) |
| |
| |
(verify) |
oxycodone (tsz. oxycodones)